Circulation and degradation of GIP and GLP-1

被引:229
作者
Deacon, CF [1 ]
机构
[1] Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; gut hormone; incretin; dipeptidyl peptidase IV; neutral endopeptidase 24.11;
D O I
10.1055/s-2004-826160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 60 条
  • [1] ADELHORST K, 1994, J BIOL CHEM, V269, P6275
  • [2] Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
    Ahrén, B
    Holst, JJ
    Mårtensson, H
    Balkan, B
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) : 239 - 245
  • [3] Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
    Ahrén, B
    Landin-Olsson, M
    Jansson, PA
    Svensson, M
    Holmes, D
    Schweizer, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) : 2078 - 2084
  • [4] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
    Ahrén, B
    Simonsson, E
    Larsson, H
    Landin-Olsson, M
    Torgeirsson, H
    Jansson, PA
    Sandqvist, M
    Båvenholm, P
    Efendic, S
    Eriksson, JW
    Dickinson, S
    Holmes, D
    [J]. DIABETES CARE, 2002, 25 (05) : 869 - 875
  • [5] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
    Balkan, B
    Kwasnik, L
    Miserendino, R
    Holst, JJ
    Li, X
    [J]. DIABETOLOGIA, 1999, 42 (11) : 1324 - 1331
  • [6] HAMSTER PREPROGLUCAGON CONTAINS THE SEQUENCE OF GLUCAGON AND 2 RELATED PEPTIDES
    BELL, GI
    SANTERRE, RF
    MULLENBACH, GT
    [J]. NATURE, 1983, 302 (5910) : 716 - 718
  • [7] ELECTRONIMMUNOCYTOCHEMICAL EVIDENCE FOR K-CELL LOCALIZATION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) IN MAN
    BUCHAN, AMJ
    POLAK, JM
    CAPELLA, C
    SOLCIA, E
    PEARSE, AGE
    [J]. HISTOCHEMISTRY, 1978, 56 (01) : 37 - 44
  • [8] ANALYSIS OF THE DEGRADATION OF INSULINOTROPIN [GLP-1(7-37)] IN HUMAN PLASMA AND PRODUCTION OF DEGRADATION RESISTANT ANALOGS
    BUCKLEY, DI
    LUNDQUIST, P
    [J]. REGULATORY PEPTIDES, 1992, 40 (02) : 117 - 117
  • [9] RADIOIMMUNOASSAY OF PLASMA GASTRIC-INHIBITORY POLYPEPTIDE (GIP), RELEASE OF GIP AFTER A TEST MEAL AND DUODENAL INFUSION OF BILE, AND IMMUNOREACTIVE PLASMA GIP COMPONENTS IN MAN
    BURHOL, PG
    JORDE, R
    WALDUM, HL
    [J]. DIGESTION, 1980, 20 (05) : 336 - 345
  • [10] CARONE FA, 1982, J LAB CLIN MED, V100, P1